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Abstract
Background: Repeated exposure to psychostimulants results in a progressive and long-lasting
facilitation of the locomotor response that is thought to have implications for addiction.
Psychostimulants and other drugs of abuse activate in specific brain areas extracellular signal-
regulated kinase (ERK), an essential component of a signaling pathway involved in synaptic plasticity
and long-term effects of drugs of abuse. Here we have investigated the role of ERK activation in
the behavioral sensitization induced by repeated administration of psychostimulants in mice, using
SL327, a brain-penetrating selective inhibitor of MAP-kinase/ERK kinase (MEK), the enzyme that
selectively activates ERK.
Results: A dose of SL327 (30 mg/kg) that reduced the number of activated ERK-positive neurons
by 62 to 89% in various brain areas, had virtually no effect on the spontaneous locomotor activity
or the acute hyperlocomotion induced by cocaine or D-amphetamine. Pre-treatment with SL327
(30 mg/kg) prior to each drug administration prevented the locomotor sensitization induced by
repeated injections of D-amphetamine or cocaine. The SL327 pre-treatment abolished also
conditioned locomotor response of mice placed in the context previously paired with cocaine or
D-amphetamine. In contrast, SL327 did not alter the expression of sensitized response to D-
amphetamine or cocaine.
Conclusion: Altogether these results show that ERK has a minor contribution to the acute
locomotor effects of psychostimulants or to the expression of sensitized responses, whereas it is
crucial for the acquisition of locomotor sensitization and psychostimulant-conditioned locomotor
response. This study supports the important role of the ERK pathway in long-lasting behavioral
alterations induced by drugs of abuse.
Background
Behavioral sensitization corresponds to a progressive
enhancement of locomotor responses following repeated
exposure to cocaine or D-amphetamine (D-amph) [1].
When established, sensitization is long-lasting since it is
observed after re-exposure to the drug several weeks or
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lie important aspects of vulnerability to drug addiction
and relapse [2,3]. In rodents sensitization was shown to
enhance predisposition to psychostimulant self-adminis-
tration [4] and to facilitate the reinstatement by drugs of
extinguished self-administration [5,6]. Behavioral sensiti-
zation is strengthened by association of psychostimulant
injections with contextual cues and context-dependent
sensitization involves different behavioral and neurobio-
logical mechanisms from context-independent sensitiza-
tion [7,8].
Processes underlying induction and expression of behav-
ioral sensitization involve a complex interplay between
various neurotransmitters and neuromodulators includ-
ing dopamine, glutamate (see [9,10]), neuropeptides and
trophic factors [11-14]. It can be hypothesized that these
converging extracellular signals give rise to a limited
number of specific molecular and cellular events that
mediate behavioral sensitization to psychostimulants.
Several lines of evidence indicate the involvement of the
ERK pathway in the integration of extracellular signals
and in the long-term effects of drugs of abuse [15,16]. ERK
is activated in reward-associated brain areas (including
nucleus accumbens (NAcc), dorsal striatum, amygdala
and prefrontal cortex, ventral tegmental area (VTA)
through combined stimulation of dopamine and gluta-
mate receptors after acute or repeated treatment with psy-
chostimulant drugs [15-21]. In the NAcc, activated ERK
controls the state of phosphorylation of transcription fac-
tors including Elk1 and cAMP response element binding
protein (CREB) and, thereby, initiates a gene transcription
program that is supposed to lead to the long-term effects
of repeated exposure to psychostimulants [22]. However,
although the role of the ERK pathway in the rewarding
properties of various drugs is well established [15,23-25],
its role in locomotor sensitization induced by repeated
drugs administration is not characterized.
In the present study we analyzed the involvement of the
ERK pathway in the locomotor responses induced by
acute and also repeated administration of psychostimu-
lants. Our results show that blockade of the ERK pathway
by the MEK inhibitor SL327 has limited effects on the
acute locomotor responses to cocaine or D-amph, but pre-
vents the induction of sensitization induced by repeated
administration of these drugs, as well as the conditioned
locomotor responses in the environment previously
paired with drug injection.
Results
Inhibition of ERK phosphorylation in the brain by systemic 
injection of SL327
To evaluate the role of the ERK pathway in the behavioral
responses to psychostimulants, we used systemic admin-
istration of the MEK inhibitor SL327 that crosses the
Table 1: Effects of SL327 on ERK phosphorylation in various brain areas (% of vehicle-treated controls)
Brain areas Vehicle SL327 (15 mg/kg) SL327 (30 mg/kg) SL327 (50 mg/kg) F(3,12)
Dorsal Striatum 100 ± 18 46 ± 10** 11 ± 6*** 0 ± 0*** 17.61
N. Accumbens Core 100 ± 16 62 ± 15 13 ± 8** 0 ± 0*** 15.55
Shell 100 ± 13 65 ± 13 23 ± 12** 0 ± 0*** 16.37
BNST Lateral 100 ± 11 52 ± 5** 18 ± 7** 0 ± 0*** 39.68
Amygdala Central 100 ± 15 62 ± 11 15 ± 13** 0 ± 0*** 16.15
Prefrontal Cortex 100 ± 10 63 ± 27 38 ± 17** 0 ± 0*** 6.34
The number of positive nuclei was counted as described in Materials and Methods, and expressed as % of the average of controls (data are means ± 
SEM, 4 mice per group). BNST: bed nucleus of the stria terminalis. ANOVA F values are indicated in the right column (for all values P < 0.01). Post-
hoc comparison of Vehicle vs SL327 was done with Bonferroni test. ** P < 0.01, *** P < 0.001.
Effects of SL327 on spontaneous locomotor activityFigure 1
Effects of SL327 on spontaneous locomotor activity. 
Locomotor activity was measured during 90 min after acute 
administration of vehicle or the MEK inhibitor SL327 (15, 30 
and 50 mg/kg). Data were analyzed with one-way ANOVA 
(F(3,92) = 10.57, P < 0.001) followed by Bonferroni test (** P < 
0.01, SL327 vs vehicle). 24 mice per group.Page 2 of 11
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Effects of SL327 on the locomotor activity induced by injection of D-amph or cocaineFigure 2
Effects of SL327 on the locomotor activity induced by injection of D-amph or cocaine. Mice pre-treated with vehi-
cle or SL327 (15, 30 and 50 mg/kg) were injected 30 min later with D-amph (2 mg/kg i.p., A, B) or cocaine (20 mg/kg i.p., C, 
D). A) Time course of D-amph-induced locomotor activity measured every 5 min is illustrated for mice pre-treated by Vehicle 
(Veh) or the highest doses of SL327 (30 mg/kg or 50 mg/kg) (10 mice per group). Time course obtained with 15 mg/kg SL327 
that was similar to that obtained with 30 mg/kg SL327 is not shown for improving legibility of the figure. Data (30 and 50 mg/kg 
SL327 and vehicle) were analyzed with a mixed factor ANOVA (repeated measure over time) (effect of SL327 F(2,216) = 43.55, 
P < 0.01). B) Total locomotor activity during the first hour after D-amph administration was analyzed with one-way ANOVA 
(F(3,36) = 5.277, P < 0.01). * P < 0.01 Vehicle (Veh) vs SL327 (50 mg/kg). C) Time course of cocaine-induced locomotor activity 
measured every 5 min for mice pre-treated by Vehicle (Veh) or SL327 (30 mg/kg or 50 mg/kg) (10 mice per group). Time 
course obtained with 15 mg/kg SL327 was similar to that obtained with 30 mg/kg SL327 (not shown in the figure). Data (30 and 
50 mg/kg SL327 and vehicle) were analyzed with a mixed factor ANOVA (repeated measure over time) (effect of SL327 F(2,216) 
= 12.745, P < 0.05). D) Total locomotor activity during the first hour after cocaine administration was analyzed with one-way 
ANOVA (F(3,36) = 1.058, NS).
BMC Neuroscience 2006, 7:20 http://www.biomedcentral.com/1471-2202/7/20blood-brain barrier [26]. We first evaluated the efficacy of
SL327 to inhibit MEK in the brain by counting the
number of neurons immunopositive for diphospho-ERK
(P-ERK) in several brain areas involved in the addictive
effects of psychostimulants [18] (Table 1). SL327 (15, 30
and 50 mg/kg, i.p.) dose-dependently reduced the
number of P-ERK-positive neurons with a similar potency
in all the regions. A significant inhibition of ERK activa-
tion was observed in all the analyzed regions of mice pre-
treated with 30 mg/kg of SL327. The inhibition was com-
plete with 50 mg/kg, as indicated by the absence of P-ERK
labeling.
Role of the ERK pathway in spontaneous and acute D-
amph- and cocaine-induced hyperlocomotion
The effects of SL327 on spontaneous locomotor activity of
mice were measured during 90 min. As illustrated in Fig-
ure 1, acute injection of SL327 at doses that significantly
inhibited ERK activation (15, 30 mg/kg, Table 1) had no
effect on the basal locomotor activity. However, at a
higher dose (50 mg/kg), SL327 reduced by about 60% the
spontaneous locomotor activity (Fig. 1).
We investigated the consequences of pre-treatment with
various doses of SL327 on the locomotor effects of D-
amph (2 mg/kg, i.p.). SL327 at dose of 15 and 30 mg/kg
slightly delayed the locomotor hyperactivity induced by
D-amph and diminished the amplitude of the peak
response (Fig. 2A, and data not shown). However, the
duration of locomotor hyperactivity was longer than in
vehicle-treated mice, and the total counts of locomotion
during a 60 min period (area under the curve after drug
injection) were not altered at the doses of 15 and 30 mg/
kg (Fig. 2B). In contrast, pre-treatment with 50 mg/kg
SL327, markedly inhibited D-amph-induced hyperloco-
motion during the first 30 min after drug administration
(Fig. 2A) leading to a significant decrease in the total
counts of D-amph-induced locomotion for 60 min (Fig.
2B).
Similar experiments were carried out using cocaine (Fig.
2C, D). The time course of cocaine locomotor responses
measured every 5 min was modified by SL327 pre-treat-
ment at doses of 15, 30 and 50 mg/kg: it was delayed and
prolonged in the presence of SL327 and the peak response
was diminished (Fig. 2C, D). However, the hyperlocomo-
tion had a longer duration and, therefore, the total loco-
motor activity induced by cocaine over a 1-hour period
was not altered by SL327 pre-treatment (Fig. 2D).
Role of the ERK pathway in the development of locomotor 
sensitization induced by D-amph
Since 30 mg/kg SL327 blocked efficiently ERK activation
and induced only a limited alteration of the acute loco-
motor response to D-amph we used this dose for examin-
Effects of SL327 on the induction and expression of locomo-tor sensitization by repeated administration of D-amphFigure 3
Effects of SL327 on the induction and expression of 
locomotor sensitization by repeated administration 
of D-amph. A) Locomotor responses were measured dur-
ing 5 consecutive days after administration of D-amph (2 mg/
kg, i.p.) 30 min after pre-treatment with vehicle (Veh) or 
SL327 (30 mg/kg), as indicated (10 mice per group). After 10 
days of withdrawal (day 15), the Veh/D-amph and SL327/D-
amph groups received an additional challenge with Veh/D-
amph or SL327/D-amph, respectively. The following day (day 
16, Additional Challenge), mice treated previously with Veh/
D-amph were challenged with D-amph in the presence of 
SL327 whereas those treated previously with SL327/D-amph 
received an injection of D-amph alone. B) Locomotor 
responses measured during 5 consecutive days after adminis-
tration of saline 30 min after pre-treatment with vehicle 
(Veh) or SL327 (30 mg/kg), as indicated (10 mice per group). 
After 10 days of withdrawal (day 15), the Veh/saline and 
SL327/saline groups received an additional treatment with 
Veh/D-amph. Data were analyzed with a mixed factor 
ANOVA (repeated measure over time): for saline group 
(Days 1–5: effect of time: F(4,90) = 2.15, NS; effect of SL327: 
F(1,90) = 1.07, NS); for D-amph group (Days 1–15: effect of 
time: F(6,126) = 13.48, P < 0.01; effect of SL327: F(1,126) = 26.21, 
P < 0.01). Bonferroni test: * P < 0.01 compared to day 1, ° P 
< 0.01 Veh/D-amph vs SL327/D-amph.Page 4 of 11
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behavioral sensitization to psychostimulants. Four groups
of mice were injected daily for 5 consecutive days in the
actimeter. Mice received D-amph or saline 30 min after
pre-treatment with SL327 or vehicle (see Materials and
Methods). The locomotor response of mice treated with
D-amph without SL327 pre-treatment enhanced progres-
sively, providing evidence of the expected behavioral sen-
sitization (Fig. 3A). By contrast, when SL327 (30 mg/kg)
was injected 30 min before each D-amph administration,
the locomotor response remained similar during the five
days (Fig. 3A). Thus, the two groups of D-amph-treated
mice, with and without SL327 pre-treatment, had a simi-
lar locomotor response the first day, but displayed signif-
icant differences the following days (Fig. 3A). In saline-
injected mice, the locomotor activity was similar after
SL327 or vehicle pre-treatment and remained stable dur-
ing the five days (Fig. 3B).
After a 10-day period of withdrawal, the maintenance of
behavioral sensitization was evaluated (day 15). As
expected, in the group of mice pre-exposed to D-amph
without SL327 the challenge with D-amph produced a
locomotor response similar to that on day 5 indicating the
maintenance of sensitization (Fig. 3A). In the group of
mice pre-exposed to D-amph in the presence of SL327, a
challenge with D-amph in the presence of SL327 did not
reveal any enhancement of locomotor response on day
15, suggesting the complete absence of locomotor sensiti-
zation by SL327/D-amph treatment. However, there was
a possibility that SL327/D-amph-treated mice developed
a sensitization to D-amph but did not express it because
the D-amph challenge was also preceded by the SL327
treatment. If it were the case, blockade of the ERK pathway
by SL327 would not impair the induction of locomotor
sensitization but only its expression. To test this possibil-
ity, an additional challenge with D-amph without SL327
pretreatment was performed on day 16 in the group of
SL327/D-amph-treated mice. This challenge produced a
low locomotor response similar to that on day 1 showing
clearly the absence of induction of sensitization to D-
amph in this group of mice. Thus, the blockade of the ERK
pathway by SL327 altered the induction of sensitization.
We examined whether this blockade affected also its
expression. To test this possibility, the mice which had
received chronic injections (5 days) of D-amph alone and
which were sensitized, as shown by their increased
response to D-amphetamine on day 15 (Fig. 3A), were
challenged with D-amph in presence of SL327 on day 16.
The injection of D-amph in the presence of SL327 on day
16 produced a locomotor response similar to that induced
by D-amph alone on day 15, revealing that blockade of
the ERK pathway had no effect on the expression of
behavioral sensitization.
Effects of SL327 on the induction and expression of locomo-tor sensitization by repeated administration of cocaineFigure 4
Effects of SL327 on the induction and expression of 
locomotor sensitization by repeated administration 
of cocaine. A) Locomotor responses measured during 5 
consecutive days after administration of cocaine (20 mg/kg, 
i.p.) 30 min after pre-treatment with vehicle (Veh) or SL327 
(30 mg/kg), as indicated (10 mice per group). After 10 days of 
withdrawal (day 15), the Veh/cocaine and SL327/cocaine 
groups received an additional treatment with Veh/cocaine 
and SL327/cocaine, respectively. B) Locomotor responses 
measured during 5 consecutive days after administration of 
saline 30 min after pre-treatment with vehicle (Veh) or 
SL327 (30 mg/kg), as indicated (10 mice per group). After 10 
days of withdrawal (day 15), the Veh/saline and SL327/saline 
groups received an additional treatment with Veh/cocaine. 
Data were analyzed with a mixed factor ANOVA (repeated 
measure over time): for saline group (effect of time: F(4,90) = 
1.66, NS; effect of SL327: F(1,90) = 1.29, NS); for cocaine 
group (effect of time: F(6,126) = 11.27, P < 0.01; effect of 
SL327: F(1,126) = 18.27, P < 0.01). Bonferroni test: * P < 0.01 
compared to day 1, ° P < 0.01 Veh/D-amph vs SL327/D-
amph.Page 5 of 11
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tion of SL327 could by itself alter the response to D-amph.
A D-amph challenge was performed after the 10-day with-
drawal period (day 15) in the mice chronically treated
with vehicle/saline or SL327/saline. The locomotor
response to D-amph in these groups was similar to that
observed in mice receiving the first injection of D-amph
(Fig. 3A, B) showing that chronic treatment by SL327 did
not alter locomotor response to D-amph after 10-day
withdrawal.
These results clearly showed that the D-amph-induced
behavioral sensitization did not develop if the ERK path-
way was blocked before each D-amph treatment. In con-
trast, when the animals were already sensitized by D-
amph, ERK blockade did not affect the expression of sen-
sitized response.
Role of the ERK pathway in the development of locomotor 
sensitization induced by cocaine
Since repeated cocaine exposure also induces a strong
locomotor sensitization, the protocol described above for
D-amph was used to evaluate whether the blockade of the
ERK pathway could affect cocaine-induced behavioral
sensitization. As expected, the locomotor response of
mice treated with cocaine without SL327 pre-treatment
progressively enhanced, showing a clear behavioral sensi-
tization (Fig. 4A). In contrast, when SL327 (30 mg/kg)
Effects of SL327 on the induction of a conditioned locomotor response to saline administrationFigure 5
Effects of SL327 on the induction of a conditioned locomotor response to saline administration. A) Locomotor 
responses measured during the first 30 min after injection of saline in mice which have received repeated injections of saline or 
D-amph, preceded by pre-treatment by vehicle (Veh) or SL327 (30 mg/kg) 30 min before (see Fig 3). Saline injection was done 
in the same actimeter in which the mice had received the repeated injections. B). Analysis of conditioned response in mice 
chronically treated with cocaine (same protocol as in A except that mice had received repeated injections of cocaine, 20 mg/kg, 
instead of D-amph). Data were analyzed with one-way ANOVA (A): F(3,36) = 8.235, P < 0.001; (B) F(3,36) = 8.585, P < 0.001, fol-
lowed by Bonferroni test: * P < 0.05, ** P < 0.01 saline vs D-amph or cocaine; ° P < 0.01 vehicle vs SL327. 10 mice per group.Page 6 of 11
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the locomotor response remained similar during the five
days (Fig. 4A).
After a 10-day period of withdrawal (day 15), we verified
by a challenge with vehicle/cocaine that the sensitization
was maintained in the group treated by repeated vehicle/
cocaine. In contrast a challenge by SL327/cocaine did not
reveal any sensitization in the group treated by repeated
SL327/cocaine. On day 16, additional challenges were
performed in these two groups of mice for investigating
the respective effects of blockade of ERK pathway on the
induction and expression of locomotor sensitization to
cocaine. Our results were essentially similar to those
obtained with D-amph. SL327 had no effect on the
expression of sensitization, i.e. it did not decrease the sen-
sitized locomotor response when it was administered just
before the challenge injection (group vehicle/cocaine,
challenge SL327/cocaine, day 16). In contrast, in mice
that had received SL327 prior to each cocaine injection
(group SL327/cocaine), the responsiveness to a challenge
injection of cocaine alone (challenge vehicle/cocaine, day
16) was identical to that observed following the first injec-
tion, supporting the role of ERK in the induction of
cocaine sensitization.
In the control groups treated with repeated vehicle/saline
or SL327/saline, the injection of cocaine ten days after the
end of chronic treatments (on day 15) produced locomo-
tor responses similar to those observed in animals receiv-
ing the first injection of cocaine (Fig. 4A, B). This showed
that chronic treatment by SL327 did not alter locomotor
response to cocaine. Altogether, these results demonstrate
that ERK is critical for the development, but not the
expression, of the cocaine-induced behavioral sensitiza-
tion.
Role of the ERK pathway in the D-amph- or cocaine-
conditioned locomotor response
During the protocol used for sensitizing mice to D-amph
or cocaine, the mice developed association between con-
text and drug effect. This was indicated by the conditioned
locomotor response seen following saline injection in the
environment associated with drug injections as compared
to an environment associated with saline injection (Fig.
5). We examined whether SL327 pre-treatment before
each drug injection during the conditioning phase could
influence the drug-conditioned locomotor response. The
conditioned response was completely abolished in mice
pre-treated with SL327 before each injection of D-amph
(Fig. 5A) or cocaine (Fig. 5B), demonstrating the critical
role of ERK in this association.
Discussion
Role of ERK activation in behavioral sensitization to 
psychostimulants
This study provides evidence of the importance of ERK
pathway in an important and characteristic long-term
behavioral changes induced by drugs of abuse, locomotor
sensitization. Drugs of abuse induce a rapid and strong
activation of ERK in a precise and limited set of brain areas
including NAcc, bed nucleus of stria terminalis, central
amygdala, prefrontal cortex [15,18]. Two ERK isoforms,
ERK1 and ERK2, are expressed in virtually every cell types.
However, ERK2 appears more specifically implicated than
ERK1 in the long-term effects of drugs since it is much
more phosphorylated than ERK1 in the striatum follow-
ing psychostimulant administration [16]. In addition,
ERK1-deficient mice that displayed a stimulus-dependent
increase in ERK2 signaling exhibited a potentiation of the
rewarding properties of morphine in the conditioned
place preference test (CPP) [27].
The strong activation of ERK induced by drugs of abuse
raises the question of its functional role. The acute loco-
motor responses were only moderately affected by the
pharmacological blockade of ERK pathway by systemic
administration of the selective MEK inhibitor, SL327. The
main effect of this inhibitor was a dose-dependent slow-
ing of the effects of psychostimulants. By contrast, MEK
blockade prevented the development, but not the expres-
sion, of the behavioral sensitization induced by repeated
exposure to psychostimulants. These results strongly sup-
port the involvement of the ERK pathway in the delayed
consequences of repeated psychostimulants administra-
tion, confirming and extending our previous finding that
ERK activation was necessary for the induction of behav-
ioral sensitization induced by a single injection of cocaine
or D-amph [16].
Role of different brain regions in ERK-dependent 
behavioral sensitization
Locomotor sensitization appears to involve several brain
regions, most of which are the site of ERK activation by
psychostimulants [9]. It has been previously reported that
acute administration of psychostimulant (cocaine and D-
amph) was able to produce an intense activation of ERK
in neurons of the NAcc, lateral bed nucleus of the stria ter-
minalis, central amygdale, deep layers of prefrontal cortex
and VTA [18-21]. It is likely that the activation of ERK in
these brain areas, or a subset of them, is critical for the
induction of locomotor sensitization.
For both cocaine and D-amph, the induction of behavio-
ral sensitization is thought to depend primarily on molec-
ular events that occur in the VTA and promote a long-
lasting increase in function of the meso-accumbens
dopamine pathway [9]. The role of ERK in the VTA is sup-Page 7 of 11
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inhibitor, PD98059, before each cocaine administration
blocked the initiation of locomotor sensitization without
altering the acute locomotor responses [12]. However,
regulation of the ERK phosphorylation in response to psy-
chostimulants is not as robust in the VTA as in the NAcc.
Indeed, it has been reported that cocaine activated ERK in
the VTA following repeated but not single injections
[17,18] whereas D-amph activated ERK in the VTA follow-
ing single but not repeated injections [21]. In addition,
ERK activation by D-amph appears to occur only in non-
dopaminergic neurons of the VTA [21]. Thus there is a
possibility that the ERK activation in other areas could
also contribute to the induction of behavioral sensitiza-
tion.
We and others have found that psychostimulant adminis-
tration produces intense ERK activation in a subset of
medium size spiny neurons in the NAcc as well as in the
dorsal striatum [15,16,19]. This regulation required com-
bined action of dopamine D1 receptors and glutamate
receptors [15,16,18-20] as well as the PKA-dependent
phosphorylation of DARPP-32, an important regulatory
protein of D1 receptor signaling cascade in the striatum,
and the inhibition of protein phosphatase-1 [16]. In the
NAcc, activation of the ERK pathway is the main factor
responsible for the induction of Fos family genes (includ-
ing c-fos, fosB and fra2), Zif268 and Egr3 in response to
cocaine, D-amph and 3,4-methylenedioxymethampheta-
mine (MDMA) [15,19,20,24]. Since these genes encode
transcription factors, ERK, by activating them, initiates a
complex program of gene regulation that participates in
the development of long-lasting effects of drugs of abuse
[20,28,29]. However, the evidence supporting the impli-
cation of NAcc in the primary events leading to the induc-
tion of sensitization is relatively weak and limited to
cocaine [30,31]. On the other hand, a number of neuroa-
daptations with possible consequences for behavioral
responses were reported to occur in the NAcc following
repeated exposure to psychostimulants. These neuroadap-
tations include functional supersensitivity of dopamine
and AMPA receptors, changes in dopamine and glutamate
release, decreased strength of cortico-striatal glutamate
synapses, alteration in dendritic morphology (for review
see [32]). Interestingly, some of these changes, such as the
functional supersensitivity of NAcc dopamine D1 recep-
tor, can be produced by repeated local infusion of D-
amph into the VTA and appear secondary to an initial
action of psychostimulants in the VTA [33]. ERK activa-
tion in the NAcc could contribute to the development of
these secondary neuroplasticity events and thereby to
alterations of NAcc neurons innervated by the VTA, which
are necessary for the expression of sensitized response.
Finally, ERK activation in the prefrontal cortex may also
be involved in locomotor sensitization. ERK is activated in
the prefrontal cortex after cocaine or D-amph administra-
tion [18,34] and this could participate in the molecular
adaptations leading to sensitization to cocaine or D-
amph, since prefrontal cortex was shown to be essential
for this effect [35-37]. Altogether, these observations sug-
gest that the ERK pathway may play a role in the develop-
ment of cocaine- and D-amph-induced behavioral
sensitization at the level of VTA and possibly of other
brain areas.
Role of ERK activation in long term behavioral effects of 
drugs of abuse
Cocaine shares with other drugs commonly abused by
humans, including morphine, nicotine and ∆9-tetrahy-
drocannabinol (THC), the property to activate ERK in the
NAcc, lateral bed nucleus of the stria terminalis, central
amygdala and deep layers of prefrontal cortex [18-21].
Other psychoactive compounds with less or no addictive
potency (caffeine, scopolamine, antidepressants and
antipsychotics) moderately activate ERK in some of these
areas, but they do not induce this combined pattern of
strong activation [18,38]. Thus, such a pattern of strong
ERK activation appears to be the hallmark of drugs of
abuse and suggests that ERK is involved in at least some of
the common long term behavioral effects of these drugs.
In support of this hypothesis, blockade of the ERK path-
way, by systemic administration of SL327 or local inhibi-
tion in the NAcc, reduced the rewarding properties of
cocaine, THC, amphetamine and MDMA evaluated by
CPP [15,23-25,39]. Here we report that ERK blockade
impairs the development of D-amph- or cocaine-induced
conditioned locomotion. This locomotor response elic-
ited by repeatedly pairing environmental context or stim-
uli with psychostimulant injections displays many
similarities with classical pavlovian conditioning, envi-
ronmental cues being the conditioned stimuli and drugs
the unconditional stimulus [40,41]. This effect appears to
result from a dopamine overflow in the NAcc following
presentation of drug-associated stimuli [42]. Our data
strongly suggest that ERK activity is required for the for-
mation of conditioned associations between environmen-
tal stimuli and drug. Recently it has been reported that the
activation of the ERK pathway in the central amygdala was
critical for cue-controlled cocaine seeking in rats [43].
Altogether these results indicate that ERK activity is
important for drug-induced pavlovian conditioning to
environmental stimuli and for the acquisition by these
stimuli of motivating properties. These behavioral proc-
esses are thought to be crucial for human addiction since
exposure to environmental stimuli previously associated
with drug-taking is a potent factor triggering drug craving
and relapse in humans [44].Page 8 of 11
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The present study provides strong evidence that ERK acti-
vation is required for the development of behavioral sen-
sitization induced by repeated administration of
psychostimulants, as well as for drug-conditioned
response. Altogether these results suggest that the ability
to activate ERK in a specific set of brain regions is an
important mechanism for the long lasting behavioral
alterations induced by drugs of abuse that contribute to
the development of addiction.
Materials and methods
Animals
Eight-week old C57BL/6J mice were from Charles River
Laboratories, L'Arbresle, France. Animals were housed
under constant temperature (22°C) and humidity (60%)
with a constant cycle of 12 h light and 12 h dark and had
free access to food and water. All experiments were per-
formed in accordance with the guidelines of the French
Agriculture and Forestry Ministry for handling animals
(decree 87849, license 01499).
Drugs
D-amphetamine sulfate (D-amph, 2 mg/kg) and cocaine
hydrochloride (20 mg/kg) (Sigma-Aldrich, St Quentin
Fallavier, France) were dissolved in saline solution (9 g/l
NaCl in water). Mice received an intraperitoneal injection
(20 ml/kg i.p.) of D-amph, cocaine or saline solution.
SL327 (Bristol-Myers Squibb, Princeton, New Jersey,
USA) was dissolved in 25% DMSO (vol/vol), diluted
twice in water (final concentration of DMSO, 12.5%) and
injected i.p. (10 ml/kg). Control mice received the same
injection of diluted DMSO without SL327 (vehicle).
Immunofluorescence
Thirty minutes after treatment with SL327 or vehicle, mice
were rapidly anaesthetized with pentobarbital (30 mg/kg,
i.p., Sanofi, France) and transcardially perfused with 4%
(weight/vol.) paraformaldehyde in 0.1 M Na2HPO4/
NaH2PO4 buffer (pH 7.5). Brains were post-fixed over-
night in the same solution as used for perfusion and
stored at 4°C. Sections (30 µm-thick) were cut with a
vibratome (Leica, France) and kept at -20°C in a solution
containing 30% (vol/vol) ethylene glycol, 30% glycerol
(vol/vol) and 0.1 M phosphate buffer. Active ERK was
immunolabeled with rabbit polyclonal antibodies against
diphospho-ERK1/2 (1:400, Cell Signaling Technology)
and Cy3-coupled secondary antibodies (1:400, Molecular
Probes) as previously described [15]. Sections were
mounted in Vectashield with DAPI counterstain (Vector
laboratories). Images were obtained using sequential laser
scanning confocal microscopy (SP2, Leica). Quantifica-
tion was performed by counting the number of cells with
a nuclear immunofluorescence above background using a
computerized image analyzer, in 2–4 brain sections per
animal, bilaterally for each region of interest.
Behavioral analysis
Measurement of locomotor activity
Locomotor responses were evaluated using a circular cor-
ridor with four infrared beams placed at every 90° (Imet-
ronic, Pessac, France) in a low luminosity environment,
avoiding stress. Locomotor activity was counted when
animals interrupted two adjacent beams and, thus, had
traveled 1/4 of the circular corridor. Locomotor activity
was measured by 5 min intervals and cumulative counts
were taken for data analysis. Mice were habituated to the
test apparatus (actimeter), handling, and procedure for
three consecutive days before the actual experiments. In
these 45-min sessions mice received saline injection 15
min after being placed in the apparatus.
Acute locomotor response
The acute locomotor effects of SL327 alone, or D-amph (2
mg/kg) or cocaine (20 mg/kg), with SL327 or vehicle pre-
treatment were evaluated on day 4 (i.e. after the 3 habitu-
ation sessions) as followed: spontaneous activity during
15 min, locomotor activity after administration of vehicle
or SL327 during 30 min and locomotor activity after injec-
tion of saline, D-amph or cocaine during 60 min.
Locomotor sensitization
Development of sensitization
For developing locomotor sensitization, mice were treated
daily with saline, D-amph (2 mg/kg) or cocaine (20 mg/
kg) for 5 consecutive days in the actimeter. Locomotor
activity was measured as follows: spontaneous activity
during 15 min, locomotor activity after administration of
vehicle or SL327 (30 mg/kg) during 30 min and locomo-
tor activity after injection of saline, D-amph or cocaine
during 60 min.
Maintenance of locomotor sensitization and effect of SL327 on 
sensitization expression
The maintenance of locomotor sensitization was evalu-
ated after 10 days of withdrawal (day 15) in the groups of
mice repeatedly exposed to D-amph or cocaine. Those
repeatedly treated in the absence of SL327 received a vehi-
cle/D-amph (2 mg/kg) or vehicle/cocaine (20 mg/kg)
treatment whereas those repeatedly treated in the pres-
ence of SL327 received a SL327/D-amph or SL327/
cocaine treatment. In addition, control groups of mice
that had repeatedly received saline injection in the pres-
ence or absence of SL327, were administered with a vehi-
cle/D-amph or vehicle/cocaine treatment. Locomotor
activity was measured using the same procedure as
described above.Page 9 of 11
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altered the expression of locomotor sensitization, the fol-
lowing day (day 16), the groups of mice previously
exposed to psychostimulant in the absence of SL327
received a SL327 pre-treatment prior to a challenge injec-
tion of the corresponding psychostimulant. As a control,
the groups of mice previously exposed to psychostimulant
in the presence of SL327 received a vehicle pre-treatment
prior to injection of the corresponding psychostimulant.
Conditioned locomotor response
Groups of mice were treated daily with saline, D-amph (2
mg/kg) or cocaine (20 mg/kg) for 5 consecutive days in
the actimeter as described above. The saline or psychos-
timulant injections were preceded 30 min before by a
vehicle or SL327 (30 mg/kg) treatment. One day after the
end of these treatments, all the mice were injected with
saline in the drug-associated environment (i.e. the circular
actimeter). Saline injections were done after a 30-min
habituation period and the locomotor activity was
recorded during 30 additional min after injection.
Statistical analysis
Groups of 4 animals and at least 10 animals were used for
immunofluorescence and behavior studies, respectively.
Behavioral results Data were analyzed with one-way
ANOVA, two-way ANOVA or mixed factor ANOVA
(repeated measure over time), as required by the experi-
mental design. Post-hoc analysis was done with Bonfer-
roni test.
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